首页> 外文期刊>Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract >Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein.
【24h】

Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein.

机译:肝癌和肝癌血栓切除术对肝细胞癌的疗效(血栓延伸至主门静脉)。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Hepatocellular carcinoma (HCC) with major portal tumor thrombus has been considered to be a fatal disease. A thrombectomy remains the only therapeutic option that offer a chance of complete tumor removal avoiding acute portal vein obstruction. However, the efficacy of tumor thrombectomy in addition to hepatectomy has not been well evaluated. METHODS: Of 979 patients who consecutively underwent initial HCC resection, 45 (4.6%) HCC patients with tumor invasion of the first branch of the portal vein (vp3) and tumor in the main portal trunk or the opposite-side portal branch (vp4) were retrospectively analyzed to evaluate the efficacy of hepatectomy and tumor thrombectomy. RESULTS: Alpha-fetoprotein, serosal invasion, and intrahepatic metastases were independently significant prognostic factors in all the 45 patients with vp3 or vp4 HCC. The 3- and 5-year survival rates in vp3 and vp4 group were 35.3% and 41.8%, and 21.2% and 20.9%, respectively. There were longer operative times and more intraoperative bleeding in patients with vp4, but no significant difference in mortality, morbidity, and survival between patients with vp3 and vp4. CONCLUSION: Hepatectomy and thrombectomy for vp4 could not only avoid acute portal occlusion due to tumor thrombus but provide a comparable survival benefit with hepatectomy for vp3.
机译:引言:具有主要门脉肿瘤血栓的肝细胞癌(HCC)被认为是致命性疾病。血栓切除术仍然是唯一可以彻底清除肿瘤而避免急性门静脉阻塞的治疗选择。然而,除肝切除术外,肿瘤血栓切除术的疗效尚未得到很好的评估。方法:在979例连续进行初次HCC切除术的患者中,有45例(4.6%)HCC患者的肿瘤侵犯了门静脉第一分支(vp3)和主门干或对侧门分支(vp4)的肿瘤回顾性分析以评估肝切除术和肿瘤血栓切除术的疗效。结果:在45例vp3或vp4肝癌患者中,甲胎蛋白,浆膜浸润和肝内转移是独立的重要预后因素。 vp3和vp4组的3年和5年生存率分别为35.3%和41.8%,以及21.2%和20.9%。 vp4患者的手术时间更长,术中出血更多,但vp3和vp4患者的死亡率,发病率和存活率无显着差异。结论:vp4肝切除和血栓切除术不仅可以避免因肿瘤血栓引起的急性门静脉阻塞,而且可以提供与vp3肝切除术相当的生存获益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号